Brief: Ocumension Therapeutics Posts FY Loss RMB402.6 Mln

Ocumension Therapeutics

30/03/2023 15:06

March 30 (Reuters) - Ocumension Therapeutics  1477.HK :
    * FY LOSS RMB402.6 MILLION VERSUS LOSS RMB260 MILLION
    * FY REVENUE RMB159.0 MILLION VERSUS RMB56.1 MILLION
    * IN TERMS OF RESEARCH AND DEVELOPMENT, WE ANTICIPATE AT
LEAST TWO
NEW PRODUCTS OF CO TO ENTER REGISTRATION STAGE IN 2023
    * IN 2023, CO IS EXPECTED TO ACCELERATE ITS DEVELOPMENT AND
EXPAND
ITS BUSINESS COMPREHENSIVELY

Source text for Eikon:  ID:nHKSbVTYF3 
Further company coverage:  1477.HK 

 ((Reuters.Briefs@thomsonreuters.com;))